Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Other Operating Expenses: 2016-2024

Historic Other Operating Expenses for Ptc Therapeutics (PTCT) over the last 9 years, with Dec 2024 value amounting to $4.5 million.

  • Ptc Therapeutics' Other Operating Expenses rose 3498.14% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.3 million, marking a year-over-year increase of 1778.07%. This contributed to the annual value of $4.5 million for FY2024, which is 96.50% down from last year.
  • Per Ptc Therapeutics' latest filing, its Other Operating Expenses stood at $4.5 million for FY2024, which was down 96.50% from $127.7 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Other Operating Expenses ranged from a high of $127.7 million in FY2023 and a low of -$23.3 million during FY2020.
  • Over the past 3 years, Ptc Therapeutics' median Other Operating Expenses value was $25.9 million (recorded in 2022), while the average stood at $52.7 million.
  • Per our database at Business Quant, Ptc Therapeutics' Other Operating Expenses soared by 5,080.00% in 2022 and then plummeted by 96.50% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Other Operating Expenses (Yearly) stood at -$23.3 million in 2020, then skyrocketed by 102.15% to $500,000 in 2021, then soared by 5,080.00% to $25.9 million in 2022, then spiked by 393.05% to $127.7 million in 2023, then plummeted by 96.50% to $4.5 million in 2024.